The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

GMAB FINANCIAL STATEMENTS

Genmab AS — balance sheet, income statement and cash flow trends

GMABGenmab AS

🇺🇸 USA · US · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income
05 B10 B15 B202120222023202420252026

Profit Funnel

Q1 2026 · TTM
Revenue3.9 B $Gross Profit3.6 B $ · 93%Operating Income1.3 B $ · 33%Pre-tax Income1 B $ · 27%Net Income821 M $ · 21%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue3.9 B $-69.7%
Gross Profit3.6 B $-70.2%
Operating Income1.3 B $-71.6%
EBITDA1.2 B $-74.9%
Net Income821 M $-84.6%

Peer Comparison· Biotechnology

CompanyRev. GrowthGross MarginEBITDA MarginNet Margin
GMAB-69.7%93.3%31.7%21.0%
Industry median4.1%84.0%-105.8%-125.7%

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
020 B40 B202120222023202420252026

Capital Structure

Q1 2026
Total Assets12.4 B
  • Equity5.7 B $46%
  • Current Liabilities1.2 B $10%
  • Long-term Liabilities5.5 B $45%

Key Figures

YoY change
Total Assets12.4 B $+105.3%
Total Liabilities6.7 B $+517.6%
Total Equity5.7 B $+14.9%
Cash & ST Investments1.5 B $-43.7%
Total Debt5.4 B $+3,776.4%
Net Debt3.8 B $—

Peer Comparison· Biotechnology

CompanyCurrent RatioDebt/EquityNetDebt/EBITDAEquity/Assets
GMAB2.1894.2%3.1045.9%
Industry median5.9010.9%1.1570.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
02.5 B5 B7.5 B202120222023202420252026

Cash Flow Bridge

Q1 2026 · TTM
-4 B-2 B0901.3 M $Operating-5.6 B $Investing4.6 B $Financing-83 M $Net Change

Key Figures

YoY change
Operating Cash Flow901.3 M $-68.5%
Capital Expenditures30 M $-72.5%
Free Cash Flow871.3 M $-68.4%
Dividends Paid——

Peer Comparison· Biotechnology

CompanyCF MarginFCF MarginCapEx RatioCF/Net Income
GMAB23.1%22.3%0.8%109.8%
Industry median-88.0%-90.9%1.9%81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on GMAB

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. This content is for informational purposes only and is not investment advice.